This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Purdy AK , Campbell KS
Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR)
Cancer Biol Ther. 2009 Dec;8(23) :2211-20
PMID: 19923897 PMCID: PMC2825280
AbstractNatural killer (NK) cells are innate immune effector cells that make up approximately 10-15% of the peripheral blood lymphocytes in humans and are primarily involved in immunosurveillance to eliminate transformed and virally-infected cells. They were originally defined by their ability to spontaneously eliminate rare cells lacking expression of class I major histocompatibility complex (MHC-I) self molecules, which is commonly referred to as "missing self" recognition. The molecular basis for missing self recognition emerges from the expression of MHC-I-specific inhibitory receptors on the NK cell surface that tolerize NK cells toward normal MHC-I-expressing cells. By lacking inhibitory receptor ligands, tumor cells or virus-infected cells that have down-modulated surface MHC-I expression become susceptible to attack by NK cells. Killer cell Ig-like receptors (KIR; CD158) constitute a family of MHC-I binding receptors that plays a major role in regulating the activation thresholds of NK cells and some T cells in humans. Here, we review the multiple levels of KIR diversity that contribute to the generation of a highly varied NK cell repertoire and explain how this diversity can influence susceptibility to a variety of diseases, including cancer. We further describe strategies by which KIR can be manipulated therapeutically to treat cancer, through the exploitation of KIR/MHC-I ligand mismatch to potentiate hematopoietic stem cell transplantation and the use of KIR blockade to enhance tumor cell killing.
NotesPurdy, Amanda K Campbell, Kerry S CA-083859/CA/NCI NIH HHS/United States CA-100226/CA/NCI NIH HHS/United States CA009035-32/CA/NCI NIH HHS/United States CA06927/CA/NCI NIH HHS/United States Research Support, N.I.H., Extramural Review United States Cancer biology & therapy Cancer Biol Ther. 2009 Dec;8(23):2211-20. Epub 2009 Dec 28.